Rituximab + Methotrexate + Cytarabine Injection
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary CNS Lymphoma
Conditions
Primary CNS Lymphoma
Trial Timeline
Nov 30, 2018 → Jun 1, 2025
NCT ID
NCT03569995About Rituximab + Methotrexate + Cytarabine Injection
Rituximab + Methotrexate + Cytarabine Injection is a phase 2 stage product being developed by Celltrion for Primary CNS Lymphoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT03569995. Target conditions include Primary CNS Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Primary CNS Lymphoma were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03569995 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Primary CNS Lymphoma